Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2015

Feb 11, 2015

30291_dirs_2015-02-11_8afa356d-7c60-47d9-8898-69f67d83bbda.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2015-02-09

Reporting Person: SCANGOS GEORGE A (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-02-09 Common Stock M 11270 Acquired 29255 Direct
2015-02-09 Common Stock F 4940 $396.88 Disposed 24315 Direct
2015-02-10 Common Stock M 18833 Acquired 43148 Direct
2015-02-10 Common Stock F 8871 $395.13 Disposed 34277 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-02-09 Restricted Stock Unit $0 M 11270 Disposed 2016-02-09 Common Stock (11270) Direct
2015-02-10 Restricted Stock Unit $0 M 18833 Disposed 2015-02-10 Common Stock (18833) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 5378 Indirect
Common Stock 5378 Indirect

Footnotes

F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

F2: There is no conversion or exercise price for this stock unit.